Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $-44.68M | $-147.05M | $-4.23 |
| 2025 | $472.3K | $-113.14M | $-5.59 |
| 2024 | $0.00 | $-78.08M | $-3.91 |
| 2023 | $251.0K | $-47.49M | $-9.73 |
| 2022 | $167.8K | $-67.63M | $-15.36 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.74 per share
Typical surprise -14.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.91 vs $-0.84miss
- Tue, Jun 30$-0.96 vs $-1.04beat
- Fri, Feb 13$-0.72 vs $-0.53miss
- Thu, Nov 13$-1.39 vs $-0.74miss
- Wed, Aug 13$-1.10 vs $-0.96miss
- Tue, Jul 1$-1.01 vs $-0.85miss
Estimates and results for HELP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
HELPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights - Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
View source ↗